ActiveSite Pharmaceuticals utilizes proprietarylead discovery technology to
discover new small molecule drug candidates (NCEs) for human diseases with
unmet medical need. Our initial efforts are focused on developing novel,
innovative treatments for diabetic macular edema and stroke.